

## SAFETY DATA SHEET

Safety data sheet according to (EC) No. 1907/2006.

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1. Product identifier:

#### Vasopressin, 8-L arginine

CAS-no.: 113-79-1

EC-no.: 204-035-4

INDEX-no.: None

REACH-REG.-no.: None.

### 1.2. Relevant identified uses of the substance or mixture and uses advised against:

For medical and veterinary research and/or commercial use. Restricted to professional users.

### 1.3. Details of the supplier of the safety data sheet:

Polypeptide Laboratories AB

Högerudsgatan 21, PO Box 30089 Phone: +46 (0) 40 36 62 00

SE-200 61 Limhamn Fax: +46 (0) 40 36 63 86

Sweden

Responsible person for the safety data sheet (e-mail): ppl@polypeptide.com

### 1.4. Emergency telephone:

Sweden: Acute: 112 – Ask for the Poison Information Centre. In less acute cases: 010 4566700 (Direct Numbers to the Poison Information Centre).

UK: NHS (England or Wales): Dial 111 or 0845 4647 NHS 24 (Scotland): Dial 111

## SECTION 2: Hazards identification

### 2.1. Classification of the substance or mixture:

Substance that are harmful if inhaled.

Vasopressin, in the form of Argipressin is the naturally occurring vasoconstrictor in man.

Special caution should always be taken in the handling of biologically active material or materials similar to those.

CLP (1272/2008): Acute Tox. 4;H332

### 2.2. Label elements:



#### WARNING

Contains: Argipressin

H332: Harmful if inhaled.

P260: Do not breathe dust.

P304+P340: IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P312: Call a POISON CENTER/doctor if you feel unwell.

### 2.3. Other hazards: None known.

PBT/vPvB: The substance is not considered PBT/vPvB according to criteria in Annex XIII.

## SECTION 3: Composition/information on ingredients

### 3.1. Substances:

| % w/w | Substance name | CAS-no.  | EC-no.    | Index-no. | REACH reg.no. | Classification    |
|-------|----------------|----------|-----------|-----------|---------------|-------------------|
| 100   | Argipressin    | 113-79-1 | 204-035-4 | -         | -             | Acute Tox. 4;H332 |

Wording of hazard statements - see section 16

---

## SECTION 4: First-aid measures

---

### 4.1. Description of first aid measures:

In case of a suspected Vasopressin exposure: **Avoid excessive drinking** until it is obvious there are no signs of water retention.

Inhalation: Move the affected person to fresh air. Keep at rest. If needed: Seek medical advice.

Skin contact: Remove contaminated clothing and wash skin with water and mild soap. If irritation persists: Seek medical advice.

Eye contact: Flush with water or physiological salt water, holding eye lids open, remember to remove contact lenses, if any. If irritation persists: Seek medical advice.

Ingestion: Rinse mouth. Avoid drinking water. Seek medical advice.

### 4.2. Most important symptoms and effects, both acute and delayed:

Harmful if inhaled. Headache, nausea and abdominal pain. May cause asthma symptoms and allergic skin reaction.

### 4.3. Indication of any immediate medical attention and special treatment needed:

Show this safety data sheet to a physician or emergency ward.

---

## SECTION 5: Fire-fighting measures

---

### 5.1. Extinguishing media:

Use water spray (never water jet), dry chemical, foam or carbon dioxide.

### 5.2. Special hazards arising from the substance or mixture:

Do not inhale smoke fumes. In case of fire, the product may form hazardous decomposition products: Carbon-, sulphur- and nitrogen oxides.

### 5.3. Advice for fire-fighters:

Use breathing apparatus with an independent source of air.

---

## SECTION 6: Accidental release measures

---

### 6.1. Personal precautions, protective equipment and emergency procedures:

Use personal protective equipment - see section 8. Avoid generation of dust. Ventilate area of leak.

### 6.2. Environmental precautions:

Do not empty into drains – see section 12. Inform appropriate authorities in accordance with local regulations.

### 6.3. Methods and material for containment and cleaning up:

Sweep up and place in a suitable container. Flush area of spill with plenty of water. Further handling of spillage - see section 13.

### 6.4. Reference to other sections:

See above.

---

## SECTION 7: Handling and storage

---

### 7.1. Precautions for safe handling:

Avoid breathing dust. Provide adequate ventilation e.g. by working in a fumehood. Do not open until use. Avoid contact with skin, eyes and clothing. Avoid generation of dust and spreading. Wash contaminated skin immediately with water and mild soap. Change contaminated clothing immediately. Take precautionary measures against static discharges.

Required access to water and eye wash fountain

### 7.2. Conditions for safe storage, including any incompatibilities:

Store in a tightly closed original container in dry and well-ventilated place. Avoid exposure to light. In, addition see manufacturer's specifications.

### 7.3. Specific end use(s):

See section 1

---

## SECTION 8: Exposure controls/Personal protection

---

**8.1. Control parameters:**

Sweden: AFS 2015:7: None

UK: Occupational exposure limits (EH40/2005 with later amendments): None

DNEL/PNEC: No CSR.

**8.2. Exposure controls:**

Appropriate engineering controls: Provide adequate ventilation e.g. by working in a fumehood.

Personal protective equipment:

Respiratory protection: During all open handling use an approved mask (EN149) with a particle filter type P3. The filter has a limited lifetime and must be changed. Read the instruction.

Skin protection: Wear protective gloves (EN374) of e.g. nitrile rubber. It has not been possible to find any data for breakthrough time, so it is recommended to change the glove if spilled on.

Eye protection: Wear tightly fitting safety goggles (EN166) in case of risk of contact with the eyes

Environmental exposure controls: None particular.

---

## SECTION 9: Physical and chemical properties

---

**9.1. Information on basic physical and chemical properties:**

|                                                        |                                           |
|--------------------------------------------------------|-------------------------------------------|
| Appearance:                                            | White amorphous powder                    |
| Odour:                                                 | No available data                         |
| Odour threshold:                                       | No available data                         |
| pH (1% aqueous solution):                              | No available data                         |
| Melting point/freezing point (°C):                     | No available data                         |
| Initial boiling point and boiling range (°C):          | Not applicable                            |
| Flash point (°C):                                      | Not applicable                            |
| Evaporation rate:                                      | Not applicable                            |
| Flammability (solid, gas):                             | No available data                         |
| Upper/lower flammability or explosive limits (vol.-%): | No available data                         |
| Vapour pressure:                                       | Not applicable                            |
| Relative density:                                      | No available data                         |
| Solubility (water):                                    | Soluble                                   |
| Partition coefficient: n-octanol/water:                | No available data                         |
| Auto-ignition temperature (°C):                        | No available data                         |
| Decomposition temperature (°C):                        | No available data                         |
| Viscosity:                                             | Not applicable                            |
| Explosive properties:                                  | Dust may form explosive mixture with air. |
| Oxidising properties:                                  | No available data                         |
| <b>9.2. Other information:</b>                         | None relevant                             |

---

## SECTION 10: Stability and reactivity

---

**10.1. Reactivity:**

No available information.

**10.2. Chemical stability:**

Stable under normal conditions - see section 7. Combustible.

**10.3. Possibility of hazardous reactions:**

Dust may form explosive mixture with air.

**10.4. Conditions to avoid:**

Strong heat, light and moisture. Avoid generation of dust.

**10.5. Incompatible materials:**

None known.

**10.6. Hazardous decomposition products:**

When heated to high temperatures (decomposition) toxic fumes are emitted: Carbon-, sulphur- and nitrogen oxides.

---

## SECTION 11: Toxicological information

---

### 11.1. Information on toxicological effects:

No toxicological data available.

Information on likely routes of exposure: Inhalation, skin and ingestion.

Symptoms:

**Inhalation:** May cause irritation of the mucous membranes. Argipressin has strong anti-diuretic properties. Symptoms may include headache, nausea, vomiting, diarrhoea, abdominal pain and cramps. Heavy exposure may cause constriction of peripheral blood vessels and contraction of smooth muscle of intestines.

**Skin:** May cause slight irritation.

**Eyes:** May cause irritation.

**Ingestion:** See under "Inhalation".

**Chronic effects:** May cause reduction of urinary excretion. Repeated or prolonged exposure, when combined with uncontrolled and excessive drinking, may cause water retention. Peptides may cause potential antigenicity and allergic reactions. Special caution should always be taken in the handling of polypeptides with hormone-like effects.

---

## SECTION 12: Ecological information

---

### 12.1. Toxicity:

No available/applicable data.

### 12.2. Persistence and degradability:

No available/applicable data.

### 12.3. Bioaccumulative potential:

No available/applicable data.

### 12.4. Mobility in soil:

No available/applicable data.

### 12.5. Results of PBT and vPvB assessment:

The substance is not considered PBT/vPvB according to criteria in Annex XIII.

### 12.6. Other adverse effects:

None known.

---

## SECTION 13: Disposal considerations

---

### 13.1. Waste treatment methods:

Disposal should be according to local, state or national legislation. Dispose of through authority facilities or pass to chemical disposal company.

**EWC-code:** 07 05 99

---

## SECTION 14: Transport information

---

Not hazardous for transportation (ADR/RID/IMDG/IATA)

**14.1. UN-no.:** None

**14.2. UN proper shipping name:** None

**14.3. Transport hazard class(es):** None

**14.4. Packing group:** None

**14.5. Environmental hazards:** None.

**14.6. Special precautions for user:** None.

**14.7. Transport in bulk according to Annex II of MARPOL and the IBC Code:** Not relevant.

---

## SECTION 15: Regulatory information

---

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture:

It is advisable not to let persons under 18 years of age work with the substance.

It is advisable not to let pregnant women work with the substance. The employer shall assess the working conditions and, if there is any risk to the safety or health and any effects on the pregnancy or breastfeeding of workers, take the necessary measures to adjust the working conditions (Directive 92/85/EEC).

Please contact national authorities regarding notification and use of the substance (Directive 2001/82/EC).

Argipressin is on WADA's list of prohibited doping substances (The World Anti-Doping Code): Group S5, DIURETICS AND MASKING AGENTS.

### 15.2. Chemical Safety Assessment:

No CSR.

---

## SECTION 16: Other information

---

### Hazard statements mentioned in section 2 and 3:

H332: Harmful if inhaled.

### Abbreviations:

CMR = Carcinogenicity, mutagenicity and reproductive toxicity.

CSR = Chemical Safety Report

DNEL = Derived No-Effect Level

EC<sub>50</sub> = Effect Concentration 50 %

FW = Freshwater

LC<sub>50</sub> = Lethal Concentration 50 %

LD<sub>50</sub> = Lethal Dose 50 %

PBT = Persistent, Bioaccumulative, Toxic

PNEC = Predicted No-Effect Concentration

vPvB = very Persistent, very Bioaccumulative

### Literature:

ECHA = REACH Registration dossier from ECHA's homepage.

EPA Ecotox = Environmental Protection Agency

IUCLID = International Uniform Chemical Database Information

RTECS = Register of Toxic Effects of Chemical Substances

<http://pro.medicin.dk>

### Training advice:

No special training is required. However, the user should be well instructed in the execution of his/her task, be familiar with this Safety Data Sheet and have normal training in the use of personal protective equipment.

### Additional information:

Prepared based on the information available to Altox A/S October 2017

### Changes since the previous edition:

Changes in sector 2 and 3. Minor changes in section 1-16

Prepared by: Altox a/s – Tonsbakken 16-18 - 2740 Skovlunde - Phone +45 - 38 34 77 98 / AP - Quality control: PW